MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases.
Help employers find you! Check out all the jobs and post your resume.
